Barclays PLC Rubius Therapeutics, Inc. Transaction History

Barclays PLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.79 - $5.98 $6,037 - $45,705	-7,643 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$4.25 - $10.4 $204,442 - $500,281	-48,104 Reduced 86.29%	7,643 $42,000
Q4 2021 Feb 14, 2022	BUY	$9.68 - $17.74 $344,278 - $630,940	35,566 Added 176.24%	55,747 $540,000
Q3 2021 Nov 09, 2021	BUY	$17.6 - $25.91 $249,444 - $367,222	14,173 Added 235.9%	20,181 $360,000
Q2 2021 Aug 13, 2021	SELL	$22.26 - $28.43 $544,501 - $695,426	-24,461 Reduced 80.28%	6,008 $146,000
Q1 2021 May 13, 2021	BUY	$8.02 - $32.01 $79,381 - $316,834	9,898 Added 48.12%	30,469 $807,000
Q4 2020 Feb 11, 2021	SELL	$4.23 - $8.73 $30,058 - $62,035	-7,106 Reduced 25.67%	20,571 $157,000
Q3 2020 Nov 12, 2020	SELL	$4.65 - $6.25 $16,474 - $22,143	-3,543 Reduced 11.35%	27,677 $140,000
Q2 2020 Aug 12, 2020	BUY	$4.01 - $6.88 $62,295 - $106,880	15,535 Added 99.04%	31,220 $187,000
Q1 2020 May 13, 2020	SELL	$3.74 - $9.84 $72,238 - $190,059	-19,315 Reduced 55.19%	15,685 $70,000
Q4 2019 Feb 10, 2020	BUY	$7.23 - $14.12 $100,966 - $197,185	13,965 Added 66.39%	35,000 $333,000
Q3 2019 Nov 14, 2019	SELL	$7.85 - $15.75 $68,907 - $138,253	-8,778 Reduced 29.44%	21,035 $164,000
Q2 2019 Aug 14, 2019	BUY	$13.5 - $19.94 $256,257 - $378,501	18,982 Added 175.26%	29,813 $468,000
Q1 2019 May 15, 2019	BUY	$13.27 - $18.51 $141,073 - $196,779	10,631 Added 5315.5%	10,831 $195,000
Q4 2018 Feb 14, 2019	SELL	$13.83 - $22.97 $60,229 - $100,034	-4,355 Reduced 95.61%	200 $3,000
Q3 2018 Nov 14, 2018	BUY	$20.06 - $26.94 $91,373 - $122,711	4,555 New	4,555 $109,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.